Eli Lilly and Company
PulseAugur coverage of Eli Lilly and Company — every cluster mentioning Eli Lilly and Company across labs, papers, and developer communities, ranked by signal.
- employs David A. Ricks 100%
- acquired by Insilico Medicine 95%
- invested by Insilico Medicine 95%
- invested in Insilico Medicine 95%
- acquired Insilico Medicine 95%
- competes with Novo Nordisk 90%
- developed by Ozempic 90%
- uses GLP-1s 90%
- acquired by Johnson & Johnson 90%
- developed by semaglutide 90%
- developed retatrutide 90%
- other Novo Nordisk 70%
- 2026-10-15 funding Eli Lilly's CEO is betting billions on new drug development to diversify revenue streams beyond the company's successful GLP-1 drugs. source
- 2026-08-05 product_launch Eli Lilly and Company reported significant revenue growth driven by its GLP-1 drugs and highlighted promising trial results for its next-generation weight-loss drug, retatrutide. source
- 2026-06-08 product_launch Eli Lilly launched LillyDirect, a direct-to-consumer platform for its weight-loss medications. source
- 2026-05-26 funding Eli Lilly is planning to acquire three vaccine development companies for nearly $4 billion. source
10 day(s) with sentiment data
-
MIT Tech Review hosts discussion on cognitive immortality
MIT Technology Review is hosting a subscriber-only roundtable discussion on the concept of cognitive immortality. The event will explore speculative methods for preserving consciousness beyond death, such as gradual bra…
-
Pharma pivots to specialized treatments amid patent cliff concerns
The pharmaceutical industry is shifting its focus from blockbuster drugs to specialized, personalized treatments due to impending patent cliffs. This strategic pivot aims to identify new revenue streams, with a target o…
-
Gen Z flocking to philanthropy studies amid wealth surge
Indiana University's Lilly Family School of Philanthropy is experiencing a significant surge in enrollment, with a 300% increase over the past decade. This growth reflects a broader trend among Gen Z students seeking ca…
-
Alphabet Stock Plummets, Dragging S&P 500 Down Amid AI Investment Concerns
Alphabet Inc. experienced its worst stock performance in over two decades, causing a significant downturn in the S&P 500 and Nasdaq Composite. This decline was triggered by the company's announcement of weaker-than-expe…
-
Alzheimer's treatments advance, but early diagnosis remains critical
New Alzheimer's treatments like lecanemab and donanemab are offering hope, but early diagnosis remains a significant hurdle. Experts highlight the need for improved diagnostic tools and accessibility to ensure patients …
-
Waters Corp. launches AI tool to accelerate pharmaceutical quality testing
Waters Corp. has launched a new AI-powered tool called Peak Integration, designed to streamline quality testing in pharmaceutical drug discovery and manufacturing. This integration within their Empower software platform…
-
Eli Lilly drug shows sleep apnea benefits; T-Mobile launches T-Mix
Two separate technology companies have made recent announcements. Eli Lilly and Company has revealed that their obesity drug, retatrutide, has shown significant benefits in reducing sleep apnea episodes during trials. S…
-
GLP-1 Medications Reshape Travel Industry: Hotels, Menus, and Wellness Adapt
The rise of GLP-1 medications like Ozempic and Wegovy is influencing the travel industry, prompting changes in hotel services and offerings. Travelers using these drugs are seeking specific amenities such as in-room med…
-
Eli Lilly CEO Bets Billions on New Drugs After GLP-1 Success
Eli Lilly's CEO, Dave Ricks, is investing heavily to replicate the success of the company's GLP-1 drugs, which propelled Eli Lilly to a $1 trillion valuation. Despite the significant revenue generated by these drugs, wh…
-
Biotech IPOs surge with over two dozen companies public this year
The biotech sector has seen a significant increase in companies going public this year, with over two dozen already having completed their IPOs. This trend is expected to continue, with more companies preparing to enter…
-
OpenAI Engineer Arrested for Espionage; Military Pursues Synthetic Blood
The FBI has arrested an OpenAI engineer on charges of espionage, alleging he planted a covert recording device. OpenAI's AI models reportedly assisted in identifying the employee. Separately, the article touches on mili…
-
GLP-1 drugs poised to outpace AI in impact and revenue
GLP-1 drugs are projected to have a more significant impact than artificial intelligence over the next two years, with sales expected to surpass generative AI revenue by the end of 2025. While initial costs were high, p…
-
Ozempic and GLP-1s Show Potential for Slowing Molecular Aging
Recent findings from Novo Nordisk and Eli Lilly suggest that GLP-1 medications, commonly used for diabetes and weight loss, may also have a beneficial effect on slowing the aging process at a molecular level. This poten…
-
Few stocks drive market gains, sparking correction or growth debate
A select few stocks are disproportionately driving the overall market's performance, raising questions about whether this trend indicates an impending market correction or the start of a new growth phase. This concentra…
-
GLP-1 weight-loss drugs linked to younger biological age, side effects under scrutiny
GLP-1 weight-loss drugs are showing potential benefits in reducing biological age, with users appearing two to three years younger than placebo groups according to research from Eli Lilly and Novo Nordisk. Despite wides…
-
Weight-loss drugs may slow biological aging, studies suggest
Weight-loss drugs like GLP-1s from Eli Lilly and Novo Nordisk are showing potential to slow biological aging, according to molecular aging clocks. These drugs, which stimulate appetite suppression, have demonstrated a r…
-
AI Enhances Antibody Design, But Lab Work Remains Crucial
Artificial intelligence has shown promise in enhancing the design of therapeutic antibodies, according to a recent study. While AI can improve existing drug candidates, the research emphasizes that traditional laborator…
-
Isomorphic Labs pioneers AI-driven drug discovery with new platform
Isomorphic Labs is developing a new AI-driven approach to drug discovery, aiming to accelerate the creation of novel medicines. The company is leveraging its proprietary AI platform, which builds upon foundational techn…
-
Anthropic's AI discovery claim sparks debate among biologists
Anthropic has claimed its AI system, Claude, has made a scientific discovery by identifying a novel repeating pattern in DNA sequences. However, this claim is contested by some biologists who argue that identifying patt…
-
New two-step method simplifies antibody-drug conjugate creation for cancer therapies
Researchers have developed a novel two-step process for creating more uniform antibody-drug conjugates (ADCs). This method precisely attaches cancer drugs to a specific site on antibodies, streamlining the development o…